Spots Global Cancer Trial Database for Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
Official Title: Phase I Dose-Escalation Drug-Interaction Study of Sorafenib and Bevacizumab in Combination With Paclitaxel in Patients With Solid Tumors
Study ID: NCT00572078
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety and tolerability and describe the maximum tolerated dose (MTD) of treatment with escalating doses of sorafenib in combination with bevacizumab and paclitaxel for patients with advanced solid tumors.
Detailed Description:
Keywords
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Indiana University Cancer Center, Indianapolis, Indiana, United States
Contact Details
Name: Safi G Shahda, MD
Affiliation: Indiana University School of Medicine
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
